Pfizer (PFE) Tops Q1 EPS by 12c; Boosts FY16 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
PFIZER REPORTS FIRST-QUARTER 2016 RESULTS
May 3, 2016 6:45 AM EDTFirst-Quarter 2016 Reported Revenues(1) of $13.0 Billion, Reflecting 26% Operational Growth Driven by 28% Operational Growth from the Innovative Products Business and the Inclusion of Legacy Hospira Operations First-Quarter 2016 Reported Revenues(1) for Pfizer Standalone (Excluding Legacy Hospira) of $11.8 Billion, Reflecting 15% Operational Growth First-Quarter 2016 Adjusted Diluted EPS(2) of $0.67, Reported Diluted EPS(1) of $0.49 Raised Midpoint of 2016 Financial Guidance Ranges for Reported Revenues(1) by $2.0 Billion and Adjusted Diluted EPS(2) by $0.18, Reflecting Strong Performance to Date and Improved Outlook for 2016 as well as Favorable Impact of Recent Changes in Foreign Exchange Rates... More
